Der er i placebokontrollerede undersøgelser med hypertensive patienter ikke set forskel i den samlede bivirkningshyppighed mellem irbesartangrupperne (56, 2%) og placebogrupperne (56, 5%).
Hypertension: in placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2%) and the placebo groups (56.5%).